A Pilot Study of the Effects of Oral Administration of Zavesca(R) on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Miglustat (Primary)
- Indications Glycogen storage disease type II; Hypersensitivity
- Focus Pharmacodynamics
- 06 Nov 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 06 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 14 Dec 2016 Status changed from not yet recruiting to recruiting.